All In Biotech

Drug Trial Radar · NCT04194775

A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma

A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of Nofazinlimab (CS1003) in Combination With Lenvatinib Compared to Placebo in Combination With Lenvatinib as First-Line Therapy in Subjects With Advanced Hepatocellular Carcinoma (HCC)

Last checked: Nov 20, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 534 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

534

Actual

Start

Dec 13, 2019

Primary completion

Jun 18, 2025

Study completion Sep 30, 2026

Sponsor

Lead sponsor
CStone PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Dec 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, double-blind, randomized, phase III study to investigate the efficacy and safety of Nofazinlimab (CS1003) in combination with lenvatinib and placebo in combination with lenvatinib in the treatment of subjects with no prior systemic treatment and with unresectable advanced hepatocellular carcinoma (HCC). Subjects cannot be eligible for locoregional therapy. In this study, Nofazinlimab (CS1003) (or placebo) and lenvatinib are both considered as the study treatment while Nofazinlimab (CS1003) (or placebo) is the investigational product and lenvatinib is selected as the basic treatment for HCC.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • Nofazinlimab (CS1003)+LenvatinibDrug

    Nofazinlimab (CS1003), intravenous (i.v.) administration every 21 days; Lenvatinib oral administration, once daily

  • Nofazinlimab (CS1003) Placebo+LenvatinibDrug

    Nofazinlimab (CS1003) Placebo, i.v. administration every 21 days ; Lenvatinib oral administration, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From enrollment to end of follow-up, a median of 42.5 months

Locations

74 sites in 6 countries. Site status is shown where the registry gives one.

  • Southern California Research Center

    Coronado, California

  • Inland Empire Liver Foundation

    Rialto, California

  • Mercy Medical Center

    Baltimore, Maryland

  • UMass Memorial Medical Center

    Worcester, Massachusetts

  • Stony Brook University Cancer Clinical Trials

    Stony Brook, New York

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • The First Affiliated Hospital Of Anhui Medical University

    Hefei, Anhui, China

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Beijing You'an Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • The 900th Hospital of Joint Logistic Support Force of PLA

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • Foshan First People's Hospital

    Foshan, Guangdong, China

  • Nanfang Hospital

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine

    Guangzhou, Guangdong, China

  • Guangxi Medical University Affiliated Tumor Hospital

    Nanning, Guangxi, China

  • Hainan General Hospital - Hepatology

    Haikou, Hainan, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Luoyang Central Hospital

    Luoyang, Henan, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Zhengzhou University - First Affiliated Hospital

    Zhengzhou, Henan, China

  • hubei Cancer Hospital

    Wuhan, Hubei, China

  • Tongji Hospital - Medical Oncology

    Wuhan, Hubei, China

  • Hunan Cancer Hospital - Radiology

    Changsha, Hunan, China

  • Hunan Provincial People's Hospital

    Changsha, Hunan, China

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • The First People's Hospital of Huai'an

    Huai'an, Jiangsu, China

  • Nantong Tumor Hospital

    Nantong, Jiangsu, China

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Yanbian University Hospital

    Yanbian, Jilin, China

  • Jinan Military Region General Hospital of the People's Liber

    Jinan, Shandong, China

  • Shangdong Provicial Qianfoshan Hospital

    Jinan, Shandong, China

  • Affiliated Hospital Of Jining Medical University

    Jining, Shandong, China

  • Linyi Cancer Hospital

    Linyi, Shandong, China

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China

  • Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China

  • Shanghai Cancer Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.